b'NGS Cancer MyMRDPanelsClinical Information Test Name within the final 3 genes are also targeted. Coupling Minimal residual disease (MRD) detection has proven to beThe MyMRD is a hotspot panel that detects all classes ofMyMRD - NGS Gene Panel Assay comprehensive gene coverage with enhanced depth of coverage, long read lengths, and the power of our robust useful in the clinical management of patients with leukemiavariants identified in a precisely defined set of targets thatMyInformatics annotation software and bioinformatics and can facilitate the development of new therapies.commonly drive myeloid malignancies including AML, MPNAssay Type database, MyMRD confidently and reproducibly detects Patients with myeloid neoplasms are typically divided intoand MDS. It can detect SNVs, indels and translocations tomutations with a mutant allele frequency of 5x10 -3 , while the genomic base pair, yielding unparalleled precision andNext-Generation Sequencing (NGS) some mutations, such as FLT3 ITDs, are detected at different prognostic groups based upon both cytogeneticsdetection of low level mutations in patients. The MyMRD-3and traditional molecular profiles; 1however, this may notCLIA-validated assay mutation allele frequencies as low at 1x10 . assay, detects at least one driver mutation in 90%-95% of all reflect the heterogeneity of disease 2that can be exploitedAMLs. This gene panel is validated to a 5x10 -3level of detection using MRD assessment. Moreover, multiple sampling is notfor all targeted sites. Method Description A completed patient consent form must be submittedfeasible for many patients and thus the development of aIndexed whole-genome libraries are hybridized withfor each sample sent to LabPMM.sensitive and reliable assay to detect several mutations withinMyMRD probes targeting mutation hotspots in a total of 23 one sample represents a significant advancement in guidinggenes (ASXL1 BRAF CALR CEBPA CSF3R DNMT3A FLT3 IDH1Indications for Testing treatment decisions. IDH2 JAK2 KIT KRAS MPL NPM1 NRAS PTPN11 RUNX1 SF3B1Identify tumor-specific markers for post-treatmentSRSF2 TP53 ZRSR2 CBFB-MYH11 KMT2A RUNX1-RUNX1T1). Inmonitoring List of Genes on the MyMRD Panel Structural Variants (Translocations and Partial Tandem addition to targeting single nucleotide variants (SNVs) and Duplications in Intronic Structures)indels in the first 21 genes, 5 structural variant breakpointsMonitor and evaluate for refractory and relapsed diseaseSNV and Indel Targets in Genes (Exons) (23 genes) CBFB-MYH11 KMT2A RUNX1-RUNX1T1ASXL1 BRAF CALR CEBPA CSF3R DNMT3A FLT3 IDH1 IDH2 JAK2 KIT KMT2A KRAS MPL MYH11 NPM1 NRAS PTPN11 RUNX1 SF3B1 SRSF2 TP53 ZRSR2 Interpretation TurnaroundSpecimen Requirements ShippingSpecimen Time Conditions StabilityAn interpretive14 to 21 3 mL of peripheral blood in Heparin,Ambient orRoom Tempreport will bebusiness days EDTA or ACD Cool; do notup to 72 issued indicating1 mL of bone marrow in Heparin,freeze hoursthe detected EDTA or ACD 2-8 C uppathogenic 1 g of purified, high qualityto 7 daysmutations and their frequenciesgenomic DNAin the interrogated sample.References1.Arber, DA et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acuteleukemia. Blood, 127(20):2391-2405.2.Sperling, AS et al. (2017). The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukemia.Nature Reviews. Cancer, 17(1):519. 52 LabPMM Services Catalog 2021|53'